Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03984396 · ClinicalTrials.gov registry record · NA
Optimal Medication Management in Alzheimer's Disease and Dementia
A NA study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 7,398
- Enrollment target
NCT03984396: Completed NA study, sponsored by Kaiser Permanente.
NCT03984396 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 7,398 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (427% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03984396, a NA study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 7,398 participants
- Enrollment target
Study Summary
The study objective is to conduct a pragmatic deprescribing intervention for people with Alzheimer's Disease or Related Dementia with Multiple Chronic Conditions (ADRD-MCC) so that these patients are on 'just right' medication regimens. The intervention will be a pragmatic, cluster randomized trial of medication optimization through increased awareness of deprescribing for the ADRD-MCC population. It will be delivered in primary care at the clinic level with a wait-list control design. As a pragmatic intervention it is designed to be relatively simple, have broad inclusion/exclusion criteria, and be implemented across the Kaiser Permanente Colorado (KPCO) system. The intervention will have two components: a patient/care partner component focused on education and activation about potential deprescribing including sending out a brochure, and a clinician component focused on increasing clinician awareness through monthly Tip Sheets about options and processes for deprescribing in the ADRD-MCC population linked to upcoming visits. The intervention will take place at 18 primary care offices in the Denver-Boulder service delivery area with 9 as initial intervention sites and 9 as delayed intervention sites.
Primary Outcome
Number of chronic medications defined as those with at least a 28 days supply
Interventions
- OTHER Educational Materials - Patient & Clinician
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,398 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2024-01-31 |
| Phase | NA |
What the finished NCT03984396 record still lists
NCT03984396 is an interventional study that assigns participants to a tested intervention. Its 7,398 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (427% higher).
The record links to 0 conditions, and to 1 intervention - of which Educational Materials - Patient & Clinician is the first listed.
NCT03984396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03984396 about?
NCT03984396 is a clinical study titled "Optimal Medication Management in Alzheimer's Disease and Dementia". The study objective is to conduct a pragmatic deprescribing intervention for people with Alzheimer's Disease or Related Dementia with Multiple Chronic Conditions (ADRD-MCC) so that these patients are on 'just right' medication regimens. The intervention will be a pragmatic, cluster randomized trial...
What is the current status of trial NCT03984396?
This trial is currently completed. It is a NA study. The enrollment target is 7,398 participants. The study started on 2019-03-06. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT03984396?
The interventions under investigation include: Educational Materials - Patient & Clinician (OTHER).
Who is sponsoring clinical trial NCT03984396?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03984396's enrollment target sits among peer trials
7,398 20th of 2000 higher than 1,981 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI